← All deals

Ansa Biotechnologies, Inc.

BiotechnologyBiotechnologyDNA SynthesisSeries B
📍 Emeryville, California, United States• Founded 2018
StreetZero Signal 81
Be the first to signal interest

About Ansa Biotechnologies, Inc.

Ansa Biotechnologies, Inc. is a biotechnology company developing enzymatic DNA synthesis technology and serving as a trusted partner for synthetic DNA production. It offers products including gene fragments up to 1 kb and emphasizes reliability with the industry’s first guaranteed on-time service. The company is headquartered in Emeryville, California, and focuses on enabling scientists to accelerate research by writing genomes rather than just reading them.

LATEST FUNDINGSeries B
$54.4M
Announced 2026-11-18
TOTAL RAISED$138.31M
🔒

Unlock the full deal profile

Create a free account to see investors, key highlights, news, company details and the AI analysis for Ansa Biotechnologies, Inc..

Free plan includes 3 full deal profiles every month.

Key highlights

  • Raised $54.4M Series B in 2025 to expand DNA synthesis capacity and commercialization.
  • Previously raised $68M Series A in April 2022 led by Northpond Ventures.
  • Offers guaranteed on-time synthetic DNA delivery and aims to synthesize every customer sequence.
  • Total funding reaches $138.31M with backing from Cerberus, RA Capital, and others.

Source document & SEC filing

The source SEC filing and the cached document are available to members only. Sign in to view and download them.

Sign in to view the filing Create free account